NCT00831376

Trough Bronchoprotection Conferred by Levosalbutamol and Racemic Salbutamol

A Proof of Concept Study to Evaluate the Trough Bronchoprotection Conferred by Chronic Dosing With Levosalbutamol and Racemic Salbutamol in Persistent Asthmatics

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 30 (actual)
• Sponsor: University of Dundee · Academic / Other
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

The objective of this study is to compare the relative bronchoprotection (at trough) conferred by 2-week chronic dosing with levosalbutamol and racemic salbutamol in mild to moderate asthmatics. Patients will be preselected into two groups on the basis of their beta-2 adrenoreceptor polymorphisms. The investigators will evaluate if this has a differential effect on the bronchoprotection conferred by both formulations of salbutamol, as evidenced by a rebound in airway hyper-responsiveness, in order to determine whether any effect can be explained by the S enantiomer in the racemic formulation.

Conditions

• Asthma

Interventions

Type	Name	Description
DRUG	levosalbutamol	Patients will be asked to take two puffs four times a day for 2 weeks
DRUG	racemic salbutamol	Patients will be asked to take two puffs four times a day for 2 weeks
DRUG	placebo	Patients will be asked to take two puffs four times a day for 2 weeks

Timeline

• Start date: 2009-01-01
• Primary completion: 2012-04-01
• Completion: 2012-04-01
• First posted: 2009-01-28
• Last updated: 2019-04-12

Locations

1 site across 1 country: United Kingdom